| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Fulvotomentoside A targets inflammatory pathways by inhibiting pro-inflammatory mediators and modulating immune responses. The compound reduces overexpression of IL-6 and IL-17A in the intestine and increases expression of Foxp3, a regulatory T cell-specific transcription factor. Its mechanism may involve modulation of the NF-κB pathway and other inflammatory signaling pathways. The compound's immunomodulatory activity makes it a promising candidate for treating inflammatory disorders.
|
|---|---|
| ln Vitro |
Fulvotomentoside A inhibits pro-inflammatory mediators in vitro. The compound reduces IL-6 and IL-17A overexpression and increases Foxp3 expression. As a triterpenoid saponin, it modulates immune responses. These in vitro findings support its potential applications in inflammation research and immunology.
|
| ln Vivo |
In vivo studies of Fulvotomentoside A are limited as the compound is primarily used as a research chemical. Its ability to reduce IL-6 and IL-17A overexpression and increase Foxp3 expression suggests potential for in vivo evaluation in models of inflammatory bowel disease and other inflammatory disorders. However, comprehensive in vivo pharmacological studies specifically targeting Fulvotomentoside A are not well documented. The compound is intended for research use only.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Fulvotomentoside A typically involve testing its anti-inflammatory activity by measuring cytokine production in immune cells. Cells are treated with varying concentrations of the compound and stimulated with inflammatory stimuli; IL-6, IL-17A, and Foxp3 levels are measured by ELISA or quantitative PCR. The compound's purity (>98%) and identity are confirmed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry.
|
| Cell Assay |
In vitro cell-based assays for Fulvotomentoside A involve culturing immune cells to evaluate its anti-inflammatory and immunomodulatory effects. Cells are treated with varying concentrations of the compound and stimulated with inflammatory stimuli. Cytokine production (IL-6, IL-17A) is measured by ELISA. Foxp3 expression is assessed by quantitative PCR or flow cytometry. Cell viability is assessed using MTT or similar colorimetric assays. All experiments are performed with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for Fulvotomentoside A would be conducted to evaluate its anti-inflammatory and immunomodulatory activities. For inflammatory bowel disease studies, animal models of colitis would be used. Parameters assessed would include intestinal inflammation, cytokine levels, and regulatory T cell populations. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Fulvotomentoside A reflect its nature as a triterpenoid saponin. It has a molecular weight of 1207.36 and the molecular formula C58H94O26. The compound has a purity of >98%. As a large glycosylated saponin, it has limited oral bioavailability. It is stored desiccated at -20°C. Complete pharmacokinetic profiling including absorption, distribution, metabolism, and excretion would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Fulvotomentoside A has been evaluated in the context of its use as a research chemical. As a naturally occurring triterpenoid saponin from Lonicera species, it is expected to have a favorable safety profile at research concentrations. The compound has a purity of >98%. Proper handling procedures including use of personal protective equipment are recommended when working with the compound. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| References | |
| Additional Infomation |
Decaisoside E has been reported in Decaisnea insignis and Decaisnea fargesii, and data are available.
Fulvotomentoside A (CAS# 150107-44-1) is also known as Decaisoside E. It has the molecular formula C58H94O26 and a molecular weight of 1207.36. The compound is a triterpenoid saponin isolated from Lonicera fulvotomentosa and Solanum torvum. Fulvotomentoside A inhibits pro-inflammatory mediators, reduces IL-6 and IL-17A overexpression, and increases Foxp3 expression. |
| Molecular Formula |
C58H94O26
|
|---|---|
| Molecular Weight |
1207.35
|
| Exact Mass |
1206.603
|
| CAS # |
150107-44-1
|
| PubChem CID |
100998349
|
| Appearance |
White to off-white solid
|
| LogP |
-1.8
|
| Hydrogen Bond Donor Count |
15
|
| Hydrogen Bond Acceptor Count |
26
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
84
|
| Complexity |
2330
|
| Defined Atom Stereocenter Count |
32
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H](CO[C@H]2O[C@H]3CC[C@]4([C@H]([C@]3(C)CO)CC[C@@]5([C@@H]4CC=C6[C@]5(CC[C@@]7([C@H]6CC(CC7)(C)C)C(=O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O)O)C)C)C)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H](CO1)O)O)O)O
|
| InChi Key |
DQDTUCJCIHGIOL-XSGUKHGCSA-N
|
| InChi Code |
InChI=1S/C58H94O26/c1-24-34(63)45(82-48-41(70)35(64)27(61)20-75-48)44(73)50(78-24)83-46-36(65)28(62)21-76-51(46)81-33-11-12-54(4)31(55(33,5)23-60)10-13-57(7)32(54)9-8-25-26-18-53(2,3)14-16-58(26,17-15-56(25,57)6)52(74)84-49-43(72)40(69)38(67)30(80-49)22-77-47-42(71)39(68)37(66)29(19-59)79-47/h8,24,26-51,59-73H,9-23H2,1-7H3/t24-,26-,27+,28-,29+,30+,31+,32+,33-,34-,35-,36-,37+,38+,39-,40-,41+,42+,43+,44+,45+,46+,47+,48-,49-,50-,51-,54-,55-,56+,57+,58-/m0/
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl] (4aS,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-3-[(2S,3R,4R,5S,6S)-3,5-dihydroxy-6-methyl-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| Synonyms |
Decaisoside E; Fulvotomentoside A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8283 mL | 4.1413 mL | 8.2826 mL | |
| 5 mM | 0.1657 mL | 0.8283 mL | 1.6565 mL | |
| 10 mM | 0.0828 mL | 0.4141 mL | 0.8283 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
